Pretreatment serum albumin-to-alkaline phosphatase ratio is an independent prognosticator of survival in patients with metastatic gastric cancer

doi:10.4251/wjgo.v14.i5.1002

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4104)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-3) series.

Item

Count

PDF

133

WORD

HTML

2531

Figures (1-5)

262

Tables (1-3)

392

Sum=3412

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

221

Download

471

Sum=692

May 15, 2022 (publication date) through May 3, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. May 15, 2022; 14(5): 1002-1013
Published online May 15, 2022. doi: 10.4251/wjgo.v14.i5.1002

Open in New Tab Full Size Figure Download Figure

Figure 1 Kaplan-Meier survival estimates between subgroups according to albumin-to-alkaline phosphatase ratio. A: Overall survival (OS) according to albumin-to-alkaline phosphatase ratio (AAPR) before propensity matching; B: Progression-free survival (PFS) according to AAPR before propensity matching; C: OS according to AAPR after propensity matching; D: PFS according to AAPR after propensity matching. AAPR: Albumin-to-alkaline phosphatase ratio.

Open in New Tab Full Size Figure Download Figure

Figure 2 Kaplan–Meier survival estimates of overall survival and progression-free survival according to albumin-to-alkaline phosphatase ratio levels in patients (A and B) without liver metastasis, (C and D) without bone metastasis, (E and F) without liver or bone metastasis. AAPR: Albumin-to-alkaline phosphatase ratio.

Open in New Tab Full Size Figure Download Figure

Figure 3 Kaplan–Meier survival estimates of overall survival and progression-free survival according to albumin-to-alkaline phosphatase ratio levels in patients with one site of metastasis. A: Overall survival according to abumin-to-alkaline phosphatase ratio (AAPR); B: Progression-free survival according to AAPR. AAPR: Albumin-to-alkaline phosphatase ratio.

Open in New Tab Full Size Figure Download Figure

Figure 4 Kaplan–Meier survival estimates of overall survival (A) and progression-free survival (B) according to the AAPR-M risk system (combination of albumin-to-alkaline phosphatase ratio and number of metastatic sites) in metastatic gastric patients.

Open in New Tab Full Size Figure Download Figure

Figure 5 Receiver operating characteristic analysis of the albumin-to-alkaline phosphatase ratio, number of metastatic sites, and AAPR-M system in 1-year overall survival (A), 2-year overall survival (B), and 1-year progression-free survival (C) prediction. PFS: Progression-free survival; OS: Overall survival; AAPR: Albumin-to-alkaline phosphatase ratio.

Citation: Li YT, Zhou XS, Han XM, Tian J, Qin Y, Zhang T, Liu JL. Pretreatment serum albumin-to-alkaline phosphatase ratio is an independent prognosticator of survival in patients with metastatic gastric cancer. World J Gastrointest Oncol 2022; 14(5): 1002-1013
URL: https://www.wjgnet.com/1948-5204/full/v14/i5/1002.htm
DOI: https://dx.doi.org/10.4251/wjgo.v14.i5.1002